Literature DB >> 15163894

Immunity in HIV-1-infected adults with a previous state of moderate-severe immune-suppression and more than 500 CD4+ T cell after highly active antiretroviral therapy.

Salvador Resino1, Laura Rivero, Ezequiel Ruiz-Mateos, Isabel Galán, Jaime Munoz Franco, Maria Angeles Munoz-Fernández, Manuel Leal.   

Abstract

We evaluated phenotypic and functional parameters of immune restoration of 27 HIV-infected patients on highly active antiretroviral therapy (HAART) (HIV-cases) with HIV-RNA levels below detectable limits at least during 18 months, and CD4+ cell per microliter higher than 500 at the moment of the study and lower than 300 anytime before. These patients were compared with 11 HIV-controls that never had less than 500 CD4+ cell per microliter and 20 healthy-controls (HIV seronegative subjects) in a cross-sectional study. HIV-cases had lower counts of naïve CD4+ than HIV-controls and healthy-controls. HIV-patients (both HIV-cases and HIV-controls) showed higher values of naïve and memory CD8+ counts than healthy-controls. TREC-bearing cell levels were significantly lower in HIV-cases than in healthy-controls. Peripheral blood mononuclear cells (PBMC) cultures, HIV-cases had lower values in proliferation to streptokinase (SK) and tetanus toxin (TT) than in healthy-controls. HIV-cases had lower IFN-gamma and higher IL-5 production with pokeweed than healthy-controls ( P < 0.01). However, IL-5 production of HIV-cases after TT stimulation was lower than in HIV-controls and healthy-controls. Total IgG and IgG1 levels were significantly higher in HIV-cases than in HIV-controls and healthy-controls. Also, IgM levels were significantly higher in HIV-cases than in healthy-controls. Nevertheless, IgG2 levels were significantly lower in HIV-cases and HIV-controls than in healthy-controls. The levels of specific Igs antipneumococcal capsular polysaccharide and TT were significantly lower in HIV-cases than in healthy-controls. HIV-patients with a previous state of severe-moderate immunosuppression normalizing their CD4+ counts have a incomplete immune reconstitution after HAART. Long-term consequences of this subclinical immune deficiency remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163894     DOI: 10.1023/B:JOCI.0000029112.82425.59

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  45 in total

1.  CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.

Authors:  Christoph G Lange; Hernan Valdez; Kathy Medvik; Robert Asaad; Michael M Lederman
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

2.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

3.  Immune function and phenotype before and after highly active antiretroviral therapy.

Authors:  S R Søndergaard; H Aladdin; H Ullum; J Gerstoft; P Skinhøj; B K Pedersen
Journal:  J Acquir Immune Defic Syndr       Date:  1999-08-15       Impact factor: 3.731

4.  Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2.

Authors:  Y Kawano; T Noma; J Yata
Journal:  J Immunol       Date:  1994-12-01       Impact factor: 5.422

5.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

6.  Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.

Authors:  A Arnó; L Ruiz; M Juan; M K Zayat; T Puig; M Balagué; J Romeu; R Pujol; W A O'Brien; B Clotet
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

7.  B cell activation during HIV-1 infection. II. Cell-to-cell interactions and cytokine requirement.

Authors:  A Amadori; R Zamarchi; M L Veronese; M Panozzo; A Barelli; A Borri; M Sironi; F Colotta; A Mantovani; L Chieco-Bianchi
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

8.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Authors:  M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

9.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

10.  Phenotypic and functional separation of memory and effector human CD8+ T cells.

Authors:  D Hamann; P A Baars; M H Rep; B Hooibrink; S R Kerkhof-Garde; M R Klein; R A van Lier
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

View more
  5 in total

1.  A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy.

Authors:  Patricia Price; Niamh M Keane; Silvia Lee; Andrew F Y Lim; Elizabeth J McKinnon; Martyn A French
Journal:  Immunology       Date:  2006-06-22       Impact factor: 7.397

2.  Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy.

Authors:  Salvador Resino; Elena Seoane; Alicia Pérez; Ezequiel Ruiz-Mateos; Manuel Leal; Maria A Muñoz-Fernández
Journal:  BMC Infect Dis       Date:  2006-07-13       Impact factor: 3.090

3.  Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy.

Authors:  A Handisurya; A Rieger; A Bankier; A Koller; A Salat; G Stingl; R Kirnbauer
Journal:  Br J Dermatol       Date:  2007-07-19       Impact factor: 9.302

4.  Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions.

Authors:  Elena Seoane; Salvador Resino; Santiago Moreno; Juan Carlos Lopez Bernaldo de Quiros; Ana Moreno; Rafael Rubio; Juan Gonzalez-García; José Ramón Arribas; Federico Pulido; Ma Angeles Muñoz-Fernández
Journal:  BMC Infect Dis       Date:  2008-02-26       Impact factor: 3.090

5.  HIV-dependent depletion of influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza immunisation.

Authors:  Adam K Wheatley; Anne B Kristensen; William N Lay; Stephen J Kent
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.